Insider Trading April 24, 2026 04:55 PM

RCM Technologies CFO Executes Planned Stock Sales Amid Near 52-Week Highs

Kevin D. Miller divests approximately $141,397 in common stock via established Rule 10b5-1 trading plan.

By Hana Yamamoto RCMT
RCM Technologies CFO Executes Planned Stock Sales Amid Near 52-Week Highs
RCMT

Kevin D. Miller, the Chief Financial Officer of RCM Technologies, Inc. (NASDAQ:RCMT), has completed two separate transactions involving the sale of company common stock. The total value of the shares sold during this period amounted to $141,397. These transactions were conducted through a nondiscretionary Rule 10b5-1 trading plan that had been previously set in place on August 12, 2024. The sales occurred as RCMT's stock price approached its 52-week high of $32.05, following a significant one-year return of 77%.

Key Points

  • CFO Kevin D. Miller sold $141,397 in RCMT shares via a pre-arranged 10b5-1 plan.
  • The stock is currently trading near its 52-week high of $32.05 after a 77% annual increase.
  • Valuation metrics like the 0.49 PEG ratio suggest the stock may be undervalued despite the recent price surge.

Kevin D. Miller, serving as the Chief Financial Officer for RCM Technologies, Inc. (NASDAQ:RCMT), has engaged in multiple transactions to sell common stock, totaling an estimated $141,397. These divestments took place over two specific dates in April 2026, with share prices fluctuating within a narrow range between $32.00 and $32.04.

The transaction details are as follows:

  • April 22, 2026: Mr. Miller sold 1,483 shares at a price point of $32.00 per share.
  • April 24, 2026: A second transaction involved the sale of 2,932 shares. These were sold at a weighted average price of $32.04, with individual prices for these transactions ranging from a low of $32.00 to a high of $32.14.

It is important to note that both sets of sales were executed as nondiscretionary transactions. These moves were part of a Rule 10b5-1 trading plan, which Mr. Miller had established on August 12, 2024. Following these recent transactions, Mr. Miller maintains a direct ownership stake in RCM Technologies consisting of 443,800 shares of common stock.


Market Context and Valuation Analysis

The timing of these insider sales coincides with a period of notable strength for RCMT. The stock is currently trading near its 52-week high of $32.05, following a robust 77% return over the previous year. However, despite this recent upward momentum and the insider selling activity, valuation metrics suggest a different perspective on the company's current pricing. According to Fair Value analysis, RCMT appears to be trading at an undervalued level, supported by a PEG ratio of 0.49.

Key Insights

  • Planned Liquidation: The use of a Rule 10b5-1 plan, established in August 2024, indicates that these sales were pre-scheduled rather than spontaneous reactions to immediate market shifts.
  • Stock Performance: RCMT has demonstrated significant momentum, yielding a 77% return over the past twelve months and approaching its yearly peak.
  • Valuation Discrepancy: While the stock is at a high, the PEG ratio of 0.49 points toward potential undervaluation relative to growth metrics.

Risks and Uncertainties

  • Price Volatility near Resistance: With the stock trading near its 52-week high of $32.05, there is inherent uncertainty regarding whether the current price level can be sustained or if it will face resistance.
  • Insider Activity Perception: While these sales were planned under a 10b5-1 plan, the movement of capital by a high-level executive like the CFO can influence market sentiment within the industrial and technology services sectors.

Risks

  • The stock is trading near its 52-week high, which can present volatility as it tests resistance levels.
  • Market sentiment may be affected by the timing of insider sales, even when conducted through automated plans.

More from Insider Trading

Insider Activity Alert: Mark E. Strome Affiliate Acquires $200,000 in Zivo Bioscience Shares Apr 24, 2026 RA Capital Healthcare Fund Divests Over 165,000 Vor Biopharma Shares Apr 24, 2026 Neonc Technologies Chief Clinical Officer Increases Equity Stake Amidst Recent Market Volatility Apr 24, 2026 NeOnc Technologies CFO Executes Share Purchase Amid Market Volatility Apr 24, 2026 BancFirst Director David Rainbolt Executes $2.1 Million Stock Sale Apr 24, 2026